Your browser doesn't support javascript.
loading
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
Choueiri, Toni K; Kluger, Harriet; George, Saby; Tykodi, Scott S; Kuzel, Timothy M; Perets, Ruth; Nair, Suresh; Procopio, Giuseppe; Carducci, Michael A; Castonguay, Vincent; Folefac, Edmund; Lee, Chung-Han; Hotte, Sebastien J; Miller, Wilson H; Saggi, Shruti Shally; Lee, Chung-Wei; Desilva, Heshani; Bhagavatheeswaran, Prabhu; Motzer, Robert J; Escudier, Bernard.
Afiliação
  • Choueiri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Toni_Choueiri@dfci.harvard.edu.
  • Kluger H; Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA.
  • George S; Department of Medical Oncology, Yale University Yale Cancer Center, New Haven, Connecticut, USA.
  • Tykodi SS; Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Kuzel TM; Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
  • Perets R; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Nair S; Division of Hematology/Oncology/Cell Therapy, Rush University Medical Center, Chicago, Illinois, USA.
  • Procopio G; Division of Oncology, Rambam Health Care Campus, Haifa, Israel.
  • Carducci MA; Technion Israel Institute of Technology, Haifa, Israel.
  • Castonguay V; Department of Hematology/Oncology, Lehigh Valley Health Network, Allentown, Pennsylvania, USA.
  • Folefac E; Division of Medical Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy.
  • Lee CH; Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
  • Hotte SJ; Department of Medicine, CHU de Quebec-Universite Laval, Montreal, Quebec, Canada.
  • Miller WH; Department of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Saggi SS; Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Lee CW; Department of Medical Oncology, Juravinski Cancer Centre, Hamilton, Ontario, Canada.
  • Desilva H; Division of Oncology, Department of Medicine, McGill University, Montreal, Québec, Canada.
  • Bhagavatheeswaran P; Department of Medicine, Division of Experimental Medicine, Jewish General Hospital, Montreal, Québec, Canada.
  • Motzer RJ; Department of Global Regulatory Science, Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Escudier B; Department of Clinical Trials, Bristol Myers Squibb, Princeton, New Jersey, USA.
J Immunother Cancer ; 10(11)2022 11.
Article em En | MEDLINE | ID: mdl-36328377
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Renais Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Renais Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos